Recce Pharmaceuticals Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives

SYDNEY, Australia, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041. “We are thrilled to receive this new family of intellectual property, granted by the Australian Patent Office, with further market monopolies reinfo

Related Keywords

United States ,Cross River ,Queensland ,Australia ,Sydney ,New South Wales ,Australian ,Andrew Geddes ,Jordyn Temperato ,James Graham ,Australian Patent Office ,Recce Pharmaceuticals ,Lifesci Communications ,Recce Pharmaceuticals Ltd ,Pharmaceuticals Ltd ,Biologically Active Copolymer ,Chief Executive Officer ,Australian Patent ,Patent Cooperation Treaty Country ,Pathogens Covered ,Varicella Zoster Virus ,New Class ,Synthetic Anti Infectives ,Infectious Disease Product ,Generating Antibiotic Initiatives Now ,Fast Track Designation ,Pew Charitable Trusts Global New Antibiotics ,Development Pipeline ,Investor Relations ,Bacterial Infections ,Viral Infections ,Lecce ,Patent Cooperation Treaty ,Viral Pathogens ,Anti Infectives ,Urinary Tract Infections ,Transdermal Delivery ,Pharmaceuticals ,